Study finds up to 94% of papillary thyroid cancers in the past three decades were overdiagnosed, with stable mortality rates, despite soaring detection rates.
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Stocktwits on MSN
IBRX stock down 10% this week, but its CEO just outlined 3 reasons bull case is intact
CEO Richard Adcock said physicians could prescribe Anktiva for papillary bladder cancer if it is added to NCCN treatment guidelines. ・The company recently filed a supplemental biologics license ...
The 2026 European Association of Urology (EAU) annual meeting featured a high risk non muscle invasive bladder cancer session and a presentation by Dr. Christian Doehn discussing the comparative ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its supplemental Biologics License ...
Please provide your email address to receive an email when new articles are posted on . A microsimulation model estimated between 72% and 94% of papillary thyroid cancer cases in the U.S. were ...
Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid ...
ImmunityBio (NasdaqGS:IBRX) has had its resubmitted supplemental Biologics License Application for ANKTIVA plus BCG in papillary non muscle invasive bladder cancer formally acknowledged by the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results